Tridolgosir

Drug Profile

Tridolgosir

Alternative Names: GD-0039

Latest Information Update: 09 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GLYCODesign
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; Colorectal cancer; Cutaneous T cell lymphoma; Head and neck cancer; Renal cancer; Viral infections

Most Recent Events

  • 09 Mar 2004 Tridolgosir is available for licensing worldwide (http://www.inflazyme.com/)
  • 12 Aug 2002 Discontinued - Preclinical for Viral infections in USA (unspecified route)
  • 23 May 2002 Discontinued - Phase-II for Chemotherapy induced damage in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top